NDAINJECTIONINJECTABLE
Approved
Oct 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
PROHANCE MULTIPACK (gadoteridol) by Bracco is magnetic resonance contrast activity [moa]. Approved for paramagnetic contrast agent [epc]. First approved in 2003.
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROHANCE MULTIPACK is a gadoteridol-based paramagnetic contrast agent administered by injection for magnetic resonance imaging (MRI) enhancement. It works by altering the magnetic properties of tissue to improve visualization of internal structures during MRI procedures. The multipack formulation provides multiple vials for institutional use in diagnostic imaging centers.
LOE Approaching
Product is in late-stage lifecycle with limited growth prospects; commercial team is likely focused on market defense and operational efficiency rather than expansion.
Mechanism of Action
Magnetic Resonance Contrast Activity
Pharmacologic Class:
Paramagnetic Contrast Agent
Indications (1)
Clinical Trials (1)
SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
Started Aug 2007
165 enrolled
Brain Metastases
Career Relevance
Working on PROHANCE MULTIPACK offers experience in late-lifecycle product management, institutional market dynamics, and generic transition strategies in the diagnostic imaging space. Career advancement is best suited for professionals seeking expertise in mature product optimization, pricing strategy, and healthcare provider relationships rather than innovative product launches.
Worked on PROHANCE MULTIPACK at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.